Last reviewed · How we verify
HPC, Cord Blood
HPC (hematopoietic progenitor cells) from umbilical cord blood engraft in the bone marrow and reconstitute the hematopoietic and immune systems.
HPC (hematopoietic progenitor cells) from umbilical cord blood engraft in the bone marrow and reconstitute the hematopoietic and immune systems. Used for Acute leukemia in remission, Chronic leukemia, Myelodysplastic syndrome.
At a glance
| Generic name | HPC, Cord Blood |
|---|---|
| Also known as | Allogeneic umbilical cord blood, hematopoietic stem cells |
| Sponsor | National Marrow Donor Program |
| Drug class | Cell therapy; hematopoietic stem cell transplant |
| Modality | Biologic |
| Therapeutic area | Oncology; Hematology |
| Phase | FDA-approved |
Mechanism of action
Cord blood-derived hematopoietic progenitor cells are infused to replace damaged or diseased bone marrow following myeloablative conditioning. These cells home to the bone marrow microenvironment, self-renew, and differentiate into all blood cell lineages, restoring hematopoietic function and immune reconstitution. Cord blood grafts offer advantages including reduced HLA matching requirements, lower graft-versus-host disease risk, and rapid availability from cryopreserved inventory.
Approved indications
- Acute leukemia in remission
- Chronic leukemia
- Myelodysplastic syndrome
- Lymphoma
- Multiple myeloma
- Severe aplastic anemia
- Inherited metabolic disorders
- Inherited immunodeficiencies
Common side effects
- Graft-versus-host disease (acute)
- Graft-versus-host disease (chronic)
- Graft failure or delayed engraftment
- Infection
- Hemorrhage
- Organ toxicity
Key clinical trials
- Expanded Access Use of Human Umbilical Cord Blood (REGENECYTE) Infusion in Patients With Chronic Fatigue of Post-COVID Condition
- A Study of Human Umbilical Cord Blood (REGENECYTE) Infusion in Patients With Post-COVID Condition (PHASE3)
- Human Umbilical Cord Blood (RegeneCyte) Infusion in Patients with Post-COVID Syndrome (PHASE2)
- Evaluation of the Safety and Efficacy of Hemacord HPC, Cord Blood in Subjects With Acute Ischemic Stroke (PHASE1)
- Centralized Cord Blood Registry to Facilitate Unrelated Cord Blood Transplantation (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- HPC, Cord Blood CI brief — competitive landscape report
- HPC, Cord Blood updates RSS · CI watch RSS
- National Marrow Donor Program portfolio CI